Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Dec 18, 2024
Product Development
Merck, iTeos dropping assets, Viridian data — BioCentury’s Clinical Report
Plus: Readouts from Sanofi-Teva, Bicycle and more
BioCentury | Jul 23, 2024
Product Development
Clinical Report: Ionis’ therapy for Angelman syndrome heading for Phase III
Plus: Data from Innovent, Agenus, Merck, Bayer and Orion
BioCentury | May 30, 2024
Product Development
Renal therapies get disease-specific
Endpoint innovation and success stories are driving a surge in renal disease drug development
BioCentury | Mar 23, 2024
Discovery & Translation
Science spotlight: AbbVie’s ADC for inflammation, plus HepaRegeniX’s liver failure therapy and more
BioCentury’s roundup of translational innovations
BioCentury | Nov 15, 2022
Finance
Nov. 15 Quick Takes: Panacea to deploy $276M in pair of funds
Plus: Acrivon’s IPO; fundings for Bonum, CG Oncology and Jnana; and pipeline updates from Arcutis and Everest
BioCentury | Mar 23, 2022
Deals
March 22 Quick Takes: Pfizer to supply UNICEF with Paxlovid
Plus Argenx’s efgartigimod meets and updates from Oric, Aligos, ITM and more
BioCentury | Aug 27, 2021
Distillery Therapeutics
Targeting MAST1 to restore cisplatin sensitivity in cancer
BioCentury | Jun 5, 2021
Targets & Mechanisms
Going beyond genetic medicines for muscular dystrophy
Muscular dystrophy programs in the clinic cover not only a range of muscle mechanisms but also anti-fibrotic and anti-inflammation ones
BioCentury | Feb 23, 2021
Product Development
Meniere disease pipeline: Data Byte
Otonomy’s negative Phase III readout calls into question the utility of targeting the glucocorticoid receptor to treat Meniere disease. There are no approved drugs to treat the disorder,
BioCentury | Sep 29, 2020
Distillery Therapeutics
Blocking glucocorticoid signaling to increase checkpoint inhibitor sensitivity
DISEASE CATEGORY: Cancer
INDICATION: Melanoma; colorectal cancer Inhibiting the glucocorticoid receptor could treat melanoma and colorectal cancer and enhance sensitivity to checkpoint
INDICATION: Melanoma; colorectal cancer Inhibiting the glucocorticoid receptor could treat melanoma and colorectal cancer and enhance sensitivity to checkpoint
Items per page:
1 - 10 of 159